Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anne F.M. Jansen is active.

Publication


Featured researches published by Anne F.M. Jansen.


Clinical Immunology | 2017

Ataxia-telangiectasia: Immunodeficiency and survival

Nienke J.H. van Os; Anne F.M. Jansen; Marcel van Deuren; Ásgeir Haraldsson; Nieke T.M. van Driel; Amos Etzioni; Michiel van der Flier; Charlotte A. Haaxma; Tomohiro Morio; Amit Rawat; Michiel H.D. Schoenaker; Annarosa Soresina; A.M.R. Taylor; Bart P. van de Warrenburg; Corry M.R. Weemaes; Nel Roeleveld; M.A.A.P. Willemsen

Ataxia-telangiectasia (AT) is a neurodegenerative disorder characterized by ataxia, telangiectasia, and immunodeficiency. An increased risk of malignancies and respiratory diseases dramatically reduce life expectancy. To better counsel families, develop individual follow-up programs, and select patients for therapeutic trials, more knowledge is needed on factors influencing survival. This retrospective cohort study of 61 AT patients shows that classical AT patients had a shorter survival than variant patients (HR 5.9, 95%CI 2.0-17.7), especially once a malignancy was diagnosed (HR 2.5, 95%CI 1.1-5.5, compared to classical AT patients without malignancy). Patients with the hyper IgM phenotype with hypogammaglobulinemia (AT-HIGM) and patients with an IgG2 deficiency showed decreased survival compared to patients with normal IgG (HR 9.2, 95%CI 3.2-26.5) and patients with normal IgG2 levels (HR 7.8, 95%CI 1.7-36.2), respectively. If high risk treatment trials will become available for AT, those patients with factors indicating the poorest prognosis might be considered for inclusion first.


Targeted Oncology | 2014

Diagnostic challenges of respiratory adverse events during everolimus treatment

Annelieke E.C.A.B. Willemsen; Filip de Vos; Anne F.M. Jansen; Maaike de Boer; Vivianne C. G. Tjan-Heijnen; Carla M.L. van Herpen

Everolimus has important clinical activity in various malignancies, but its use can be complicated by respiratory adverse events. Important everolimus-induced respiratory adverse events are interstitial lung disease (ILD) and infections, either typical or opportunistic. Furthermore, non-everolimus-related respiratory events can occur. Due to the non-specific presentation of most of these respiratory disorders, it is often not possible to differentiate between these causes on clinical and radiological grounds only. Considering the potential fatal nature of opportunistic infections, these are especially important to recognize. To be able to distinguish between ILD and (opportunistic) infections as the underlying cause, an aggressive diagnostic workup, including bronchoalveolar lavage, should be performed in patients treated with everolimus who develop respiratory disease. We report three cases of severe opportunistic pulmonary infections during everolimus treatment, concerning two Pneumocystis jirovecii pneumonia infections. These cases illustrate the diagnostic challenges of respiratory adverse events and the importance of a thorough diagnostic workup for correct diagnosis and treatment.


BMC Infectious Diseases | 2017

CXCL9, a promising biomarker in the diagnosis of chronic Q fever

Anne F.M. Jansen; Teske Schoffelen; Julien Textoris; Jean-Louis Mege; Marrigje H. Nabuurs-Franssen; Ruud P. H. Raijmakers; Mihai G. Netea; Leo A. B. Joosten; Chantal P. Bleeker-Rovers; Marcel van Deuren

BackgroundIn the aftermath of the largest Q fever outbreak in the world, diagnosing the potentially lethal complication chronic Q fever remains challenging. PCR, Coxiella burnetii IgG phase I antibodies, CRP and 18F–FDG-PET/CT scan are used for diagnosis and monitoring in clinical practice. We aimed to identify and test biomarkers in order to improve discriminative power of the diagnostic tests and monitoring of chronic Q fever.MethodsWe performed a transcriptome analysis on C. burnetii stimulated PBMCs of 4 healthy controls and 6 chronic Q fever patients and identified genes that were most differentially expressed. The gene products were determined using Luminex technology in whole blood samples stimulated with heat-killed C. burnetii and serum samples from chronic Q fever patients and control subjects.ResultsGene expression of the chemokines CXCL9, CXCL10, CXCL11 and CCL8 was strongly up-regulated in C. burnetii stimulated PBMCs of chronic Q fever patients, in contrast to healthy controls. In whole blood cultures of chronic Q fever patients, production of all four chemokines was increased upon C. burnetii stimulation, but also healthy controls and past Q fever individuals showed increased production of CXCL9, CXCL10 and CCL8. However, CXCL9 and CXCL11 production was significantly higher for chronic Q fever patients compared to past Q fever individuals. In addition, CXCL9 serum concentrations in chronic Q fever patients were higher than in past Q fever individuals.ConclusionCXCL9 protein, measured in serum or as C. burnetii stimulated production, is a promising biomarker for the diagnosis of chronic Q fever.


Clinical Immunology | 2016

Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective.

Anne F.M. Jansen; Marcel van Deuren; Joanne Miller; Jiří Litzman; Javier de Gracia; Matías Sáenz-Cuesta; Anna Szaflarska; Timi Martelius; Yuichi Takiguchi; Smita Y. Patel; Siraj Misbah; Anna Simon

Good syndrome (GS) or thymoma-associated immunodeficiency, is a rare condition that has only been studied in retrospective case series. General consensus was that GS has a worse prognosis than other humoral immunodeficiencies. In this study, physicians of GS patients completed two questionnaires with a two year interval with data on 47 patients, 499 patient years in total. Results on epidemiology, disease characteristics, and outcome are presented. Mean age at diagnosis was 60years and median follow-up from onset of symptoms was 9years. There was a high frequency of respiratory tract infections due to encapsulated bacteria. Median survival was 14years. Survival was reduced compared to age-matched population controls (5-year survival: 82% versus 95%, p=0.008). In this cohort survival was not associated with gender (HR 0.9, 95% CI 0.3-3.0), autoimmune diseases (HR 2.9, 95% CI 0.8-10.1) or immunosuppressive use (HR 0.3, 95% CI: 0.1-1.2).


European Neuropsychopharmacology | 2018

Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals

M.J. Bakker-Huvenaars; C.U. Greven; P. Herpers; E. Wiegers; Anne F.M. Jansen; R. van der Steen; A.E. van Herwaarden; A.N. Baanders; K.S. Nijhof; F. Scheepers; N. Rommelse; Jeffrey C. Glennon; Jan K. Buitelaar

The aim of the current study was to compare levels of oxytocin, cortisol, and testosterone in adolescents with either autism spectrum disorder (ASD), or oppositional defiant disorder (ODD)/conduct disorder (CD), and in typically developing individuals (TDI), and relate hormone levels to severity and subtype of aggression and callous-unemotional (CU) traits. Saliva concentrations of oxytocin, cortisol, and testosterone were assessed in 114 male participants (N = 49 ASD, N = 37 ODD/CD, N = 28 TDI,) aged 12-19 years (M = 15.4 years, SD = 1.9). The ASD and the ODD/CD groups had significantly lower levels of oxytocin than the TDI group, and the ODD/CD group had significantly higher levels of testosterone than the ASD group. There were no group effects on cortisol levels. Group differences remained for oxytocin after correcting for the influence of CU traits, but were not significant after controlling for aggression. Results for testosterone became non-significant after correction for either CU traits or aggression. Across groups, higher levels of CU traits were related to higher levels of cortisol and testosterone, however, proactive and reactive aggression were unrelated to all three hormonal levels. The current findings show that, regardless of cognitive ability or comorbid disorders, the diagnostic groups (ASD, ODD/CD) differ from each other by their hormonal levels, with the ASD group characterized by relative low level of oxytocin, and the ODD/CD group by a relative low level of oxytocin and high level of testosterone. These group effects were partly driven by differences in CU traits between the groups.


European Journal of Internal Medicine | 2018

Autoimmunity and B-cell dyscrasia in acute and chronic Q fever: A review of the literature

Anne F.M. Jansen; Ruud P. H. Raijmakers; Stephan P. Keijmel; Renate G. van der Molen; Gerald Vervoort; Jos W. M. van der Meer; Marcel van Deuren; Chantal P. Bleeker-Rovers

Q fever infection can lead to chronic Q fever, a potentially lethal disease occurring in 1-5% of patients infected with Coxiella burnetii, characterized by the persistence of this intracellular bacterium. It usually presents as endocarditis, infected vascular aneurysms, or infected vascular prostheses. This systematic review of the literature discusses the various autoimmune syndromes and B-cell dyscrasias in acute and chronic Q fever patients, that may interfere with or impede recognition and diagnosis of Q fever. Reportedly, high concentrations of anti-cardiolipin antibodies may be found in acute Q fever patients, while specifically cardiac muscle antibodies have been reported during chronic Q fever. Systemic lupus erythematosus and antiphospholipid syndrome are the most frequently reported autoimmune syndromes, followed by neuromuscular disorders and vasculitis. B-cell dyscrasia, mostly cryoglobulinaemia, is predominantly described in chronic Q fever patients with endocarditis. We conclude that immunological (epi)phenomena are not rare during Q fever and may obscure the infectious etiology of the disease.


Cell | 2016

Host and Environmental Factors Influencing Individual Human Cytokine Responses

Rob ter Horst; Martin Jaeger; Sanne P. Smeekens; Marije Oosting; Morris A. Swertz; Yang Li; Vinod Kumar; Dimitri A. Diavatopoulos; Anne F.M. Jansen; Heidi Lemmers; Helga Toenhake-Dijkstra; Antonius E. van Herwaarden; Matthijs Janssen; Renate G. van der Molen; Irma Joosten; Fred C.G.J. Sweep; Johannes W. A. Smit; Romana T. Netea-Maier; Mieke M.J.F. Koenders; Ramnik J. Xavier; Jos W. M. van der Meer; Charles A. Dinarello; Norman Pavelka; Cisca Wijmenga; Richard A. Notebaart; Leo A. B. Joosten; Mihai G. Netea


Cell | 2016

A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans

Yang Li; Marije Oosting; Sanne P. Smeekens; Martin Jaeger; Raúl Aguirre-Gamboa; Kieu T.T. Le; Patrick Deelen; Isis Ricaño-Ponce; Teske Schoffelen; Anne F.M. Jansen; Morris A. Swertz; Sebo Withoff; Esther van de Vosse; Marcel van Deuren; Frank L. van de Veerdonk; Alexandra Zhernakova; Jos W. M. van der Meer; Ramnik J. Xavier; Lude Franke; Leo A. B. Joosten; Cisca Wijmenga; Vinod Kumar; Mihai G. Netea


Infection and Immunity | 2018

Viable Coxiella burnetii Induces Differential Cytokine Responses in Chronic Q Fever Patients Compared to Heat-Killed Coxiella burnetii

Anne F.M. Jansen; Annemieke Dinkla; Hendrik-Jan Roest; Chantal P. Bleeker-Rovers; Teske Schoffelen; Leo A. B. Joosten; Peter C. Wever; Marcel van Deuren; Ad P. Koets


European Journal of Clinical Microbiology & Infectious Diseases | 2018

Interferon-gamma and CXCL10 responses related to complaints in patients with Q fever fatigue syndrome

Ruud P. H. Raijmakers; Anne F.M. Jansen; Stephan P. Keijmel; Teske Schoffelen; A. Scholzen; J.W.M. van der Meer; Leo A. B. Joosten; Mihai G. Netea; M. van Deuren; Chantal P. Bleeker-Rovers

Collaboration


Dive into the Anne F.M. Jansen's collaboration.

Top Co-Authors

Avatar

Marcel van Deuren

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Leo A. B. Joosten

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mihai G. Netea

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Teske Schoffelen

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cisca Wijmenga

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Marije Oosting

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Martin Jaeger

Radboud University Nijmegen

View shared research outputs
Researchain Logo
Decentralizing Knowledge